Original Research
Published on 22 Mar 2022
The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1low Mice
in Cancer Molecular Targets and Therapeutics
- 4,533 views
- 11 citations
Original Research
Published on 22 Mar 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 22 Mar 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 17 Mar 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 17 Mar 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 17 Mar 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 16 Mar 2022
in Cancer Molecular Targets and Therapeutics
Review
Published on 16 Mar 2022
in Cancer Molecular Targets and Therapeutics
Review
Published on 16 Mar 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 16 Mar 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 14 Mar 2022
in Cancer Molecular Targets and Therapeutics
Editorial
Published on 14 Mar 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 11 Mar 2022
in Cancer Molecular Targets and Therapeutics
Review
Published on 10 Mar 2022
in Cancer Molecular Targets and Therapeutics
Brief Research Report
Published on 10 Mar 2022
in Cancer Molecular Targets and Therapeutics
Original Research
Published on 10 Mar 2022
in Cancer Molecular Targets and Therapeutics
Review
Published on 04 Mar 2022
in Cancer Molecular Targets and Therapeutics